EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model

Nidhi Seegobin, Laura E McCoubrey, Cécile Vignal, Christophe Waxin, Youssef Abdalla, Yue Fan, Atheer Awad, Sudaxshina Murdan, Abdul W Basit iD

Drug Delivery and Translational Research · 2025-07 · 15 (7) · 2372-2389

DOI: 10.1007/s13346-024-01736-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 11.11.2024. Verfasst von Nidhi Seegobin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, 29-39 Brunswick Square, London, UK. Hauptthemen laut MEDLINE: Polylactic Acid-Polyglycolic Acid Copolymer, Colitis, Nanoparticles, Pyrimidines. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Interreg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) affects over 7 million people worldwide and significant side effects are associated with current therapies such as tofacitinib citrate (TFC), which is linked to increased risks of malignancy and congestive heart issues. To mitigate these systemic adverse effects, localised drug delivery via nano-sized carriers to inflamed gut tissues represents a promising approach. Herein, we aimed to optimise the synthesis of nanoparticles (NPs) using a low molecular weight grade of Poly(lactic-co-glycolic acid) (PLGA) 50:50 loaded with TFC. This approach leverages the dual anti-inflammatory action of TFC and the local production of anti-inflammatory short-chain fatty acids from the degradation of PLGA by colonic gut microbiota. NPs were produced by nanoprecipitation and characterised for their drug release profile in vitro. The efficacy of the enhanced PLGA-TFC NPs was then tested in a C57BL/6 DSS colitis mouse model. The release profile of TFC from the enhanced PLGA NPs showed a 40% burst release within the first hour, followed by up to 80% drug release in the colonic environment. Notably, the degradation of PLGA by colonic gut microbiota did not significantly influence TFC release. In the mouse model, neither PLGA NPs alone nor TFC alone showed significant effects on weight loss compared to the TFC-loaded PLGA NPs, emphasising the enhanced efficacy potential of the combined formulation. Altogether, these results suggest a promising role of NP delivery systems in enhancing TFC efficacy, marking a significant step towards reducing dosage and associated side effects in IBD treatment. This study underscores the potential of PLGA-TFC NPs in providing targeted and effective therapy for IBD. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polylactic Acid-Polyglycolic Acid CopolymerColitisNanoparticlesPyrimidinesPiperidinesInflammatory Bowel DiseasesPyrrolesAnti-Inflammatory AgentsAnimalsMice, Inbred C57BLDisease Models, AnimalDrug LiberationMiceDextran SulfateDrug CarriersGastrointestinal Microbiome

Stichwörter der Autor:innen

Colonic drug delivery and targetingInflammatory bowel diseaseMicrobiome medicineMurine model of acute colitisNanoparticlesNanoprecipitationPLGATofacitinib

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymertofacitinibPyrimidinesPiperidinesDextran SulfateDrug CarriersPyrrolesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, 29-39 Brunswick Square, London, UK.
  • Drug Product Development, GSK R&D, Ware, SG12 0GX, UK.
  • Univ. Lille, Inserm, CHU Lille, UMR1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France.
  • Department of Clinical, Pharmaceutical and Biological Sciences, University of Hertfordshire, College Lane, Hatfield, AL10 9AB, UK.
  • Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, 29-39 Brunswick Square, London, UK. a.basit@ucl.ac.uk.

ORCID-Profile: Abdul W Basit

Förderung

  • Engineering and Physical Sciences Research Council
  • Interreg

Zitieren

APA

Seegobin, N., McCoubrey, L. E., Vignal, C., Waxin, C., Abdalla, Y., Fan, Y., Awad, A., Murdan, S., & Basit, A. W. (2025). Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model. Drug Delivery and Translational Research, 15(7), 2372-2389. https://doi.org/10.1007/s13346-024-01736-1

Vancouver

Seegobin N, McCoubrey LE, Vignal C, Waxin C, Abdalla Y, Fan Y, et al. Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model. Drug Delivery and Translational Research. 2025;15(7):2372-2389. doi:10.1007/s13346-024-01736-1

BibTeX
@article{Seegobin2025,
  author = {Seegobin, Nidhi and McCoubrey, Laura E and Vignal, Cécile and Waxin, Christophe and Abdalla, Youssef and Fan, Yue and Awad, Atheer and Murdan, Sudaxshina and Basit, Abdul W},
  title = {Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {2372--2389},
  doi = {10.1007/s13346-024-01736-1}
}
Kostenlos starten →